A more nuanced, dual-threshold approach based on a patient’s risk profile can improve the use of a noninvasive assay for Pneumocystis jirovecii pneumonia (PJP), according to the results of a recent study.
Early diagnosis and timely treatment of PJP is crucial but challenging, particularly among HIV-negative patients who may have atypical presentations and a broad list of differential diagnoses. Noninvasive tests, such as the (1→3)-beta-D-glucan (BDG) assay (Fungitell,